LENZ Therapeutics (LENZ) Competitors $38.26 -2.19 (-5.41%) Closing price 04:00 PM EasternExtended Trading$38.67 +0.41 (+1.08%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. MTSR, PCVX, KRYS, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, and ZLABShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Metsera (MTSR), Vaxcyte (PCVX), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors Metsera Vaxcyte Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab LENZ Therapeutics (NASDAQ:LENZ) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Do analysts recommend LENZ or MTSR? LENZ Therapeutics currently has a consensus target price of $52.80, suggesting a potential upside of 38.00%. Metsera has a consensus target price of $55.75, suggesting a potential upside of 5.21%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Metsera 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders and institutionals have more ownership in LENZ or MTSR? 54.3% of LENZ Therapeutics shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, LENZ or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-20.14MetseraN/AN/A-$209.13MN/AN/A Does the media prefer LENZ or MTSR? In the previous week, LENZ Therapeutics had 2 more articles in the media than Metsera. MarketBeat recorded 3 mentions for LENZ Therapeutics and 1 mentions for Metsera. Metsera's average media sentiment score of 0.85 beat LENZ Therapeutics' score of 0.47 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Metsera 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LENZ or MTSR more profitable? Metsera's return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% Metsera N/A N/A N/A SummaryLENZ Therapeutics beats Metsera on 7 of the 10 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.41B$6.08B$10.54BDividend YieldN/A2.29%5.73%4.78%P/E RatioN/A22.5884.6327.10Price / SalesN/A484.96606.15130.49Price / CashN/A46.9737.8662.13Price / Book5.1610.4112.246.58Net Income-$49.77M-$52.47M$3.32B$276.75M7 Day Performance-1.37%2.30%0.76%0.92%1 Month Performance-9.40%14.45%8.03%4.20%1 Year Performance45.36%12.90%71.13%37.86% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics2.0653 of 5 stars$38.26-5.4%$52.80+38.0%+48.4%$1.15BN/A-20.14110MTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081PCVXVaxcyte2.1446 of 5 stars$41.21-3.4%$106.25+157.8%-63.0%$5.35BN/A-10.03160Analyst ForecastKRYSKrystal Biotech4.7815 of 5 stars$180.57-1.5%$209.00+15.7%+5.9%$5.31B$359.21M36.70210News CoveragePositive NewsAnalyst ForecastPTCTPTC Therapeutics3.6136 of 5 stars$64.80-0.9%$69.00+6.5%+82.1%$5.19B$1.76B9.301,410ARWRArrowhead Pharmaceuticals3.8766 of 5 stars$37.50+3.8%$43.14+15.0%+84.7%$4.99B$3.55M-29.30400ACLXArcellx2.3371 of 5 stars$84.38-0.8%$114.31+35.5%-4.5%$4.72B$107.94M-24.6780Analyst ForecastKYMRKymera Therapeutics1.0115 of 5 stars$57.55-0.6%$61.26+6.5%+23.3%$4.14B$47.07M-16.58170Analyst ForecastInsider TradePTGXProtagonist Therapeutics1.7495 of 5 stars$64.14-1.1%$68.36+6.6%+61.2%$4.03B$209.18M91.63120Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.2192 of 5 stars$41.68+2.0%$74.45+78.6%-28.1%$3.93B$1.39M-10.14210ZLABZai Lab2.7822 of 5 stars$33.31-1.3%$56.35+69.2%+10.2%$3.77B$398.99M-16.331,869News CoverageGap Up Related Companies and Tools Related Companies MTSR Competitors PCVX Competitors KRYS Competitors PTCT Competitors ARWR Competitors ACLX Competitors KYMR Competitors PTGX Competitors CRNX Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
